Behind the Science: Behind Breaking the Cycle of Recurrent C Difficile
The healthcare-associated infection, C difficile, can be especially problematic for patients and clinicians. It is estimated that between 15% to 30% of patients who respond to antibiotics experience recurrent C difficile. And a second recurrence rate of 40% can happen to those who have a resolved first recurrence. This subset of patients who get additional recurrences can begin to experience a revolving door of healthcare interactions, diminished quality of life, and severe health consequences. In this video segment, clinicians and stakeholders offer some insights for how a biotherapeutic could help these patients.
Related Articles
- Deep Dive: Into Improving Patient Outcomes Through AI
August 16th 2023
- Behind the Science: Behind Chemotherapy Shortages
August 15th 2023
- Deep Dive: Into Types of Chromatography
August 15th 2023
- Deep Dive: Into Clinical Trials & Reproductive Health
August 4th 2023
- Deep Dive: Into Diabetic Retinopathy
August 3rd 2023
- Deep Dive: Into AHN’s Fertility Clinic
August 2nd 2023